Literature DB >> 23810952

Riccardin D induces cell death by activation of apoptosis and autophagy in osteosarcoma cells.

Yanyan Wang1, Yuan Ji, Zhongyi Hu, Hanming Jiang, Fanghua Zhu, Huiqing Yuan, Hongxiang Lou.   

Abstract

Macrocyclic bisbibenzyls, characteristic components derived from liverworts, have various biological activities. Riccardin D (RD), a liverwort-derived naturally occurring macrocyclic bisbibenzyl, has been found to exert anticancer effects in multiple cancer cell types through apoptosis induction. However, the underlying mechanisms of such effects remain undefined. In addition, whether RD induces other forms of cell death such as autophagy is unknown. In this study, we found that the arrest of RD-caused U2OS (p53 wild) and Saos-2 (p53 null) cells in G1 phase was associated with the induction of p53 and p21(WAF1) in U2OS cells. RD-mediated cell cycle arrest was accompanied with apoptosis promotion as indicated by changes in nuclear morphology and expression of apoptosis-related proteins. Further studies revealed that the antiproliferation of RD was unaffected in the presence of p53 inhibitor but was partially reversed by a pan-inhibitor of caspases, suggesting that p53 was not required in RD-mediated apoptosis and that caspase-independent mechanisms were involved in RD-mediated cell death. Except for apoptosis, RD-induced autophagy occurred as evidenced by the accumulation of microtubule-associated protein-1 light chain-3B-II, formation of AVOs, punctate dots, and increased autophagic flux. Pharmacological blockade of autophagy activation markedly attenuated RD-mediated cell death. RD-induced cell death was significantly restored by the combination of autophagy and caspase inhibitors in osteosarcoma cells. Overall, our study revealed RD-induced caspase-dependent apoptosis and autophagy in cancer cells, as well as highlighted the importance of continued investigation on the use of RD as a potential anticancer candidate.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Apoptosis; Autophagy; Cell cycle arrest; Riccardin D; p53

Mesh:

Substances:

Year:  2013        PMID: 23810952     DOI: 10.1016/j.tiv.2013.06.001

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  7 in total

1.  The natural sweetener metabolite steviol inhibits the proliferation of human osteosarcoma U2OS cell line.

Authors:  Jun-Ming Chen; Jue Zhang; Yong-Mei Xia; Xiao-Xia Wang; Jian Li
Journal:  Oncol Lett       Date:  2018-02-06       Impact factor: 2.967

2.  Dendropanoxide induces autophagy through ERK1/2 activation in MG-63 human osteosarcoma cells and autophagy inhibition enhances dendropanoxide-induced apoptosis.

Authors:  Ji-Won Lee; Kyoung-Sook Kim; Hyun-Kyu An; Cheorl-Ho Kim; Hyung-In Moon; Young-Choon Lee
Journal:  PLoS One       Date:  2013-12-17       Impact factor: 3.240

Review 3.  Elaborating the role of natural products-induced autophagy in cancer treatment: achievements and artifacts in the state of the art.

Authors:  Ning Wang; Yibin Feng
Journal:  Biomed Res Int       Date:  2015-03-03       Impact factor: 3.411

Review 4.  Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases.

Authors:  Chetan Kumar Jain; Hemanta Kumar Majumder; Susanta Roychoudhury
Journal:  Curr Genomics       Date:  2017-02       Impact factor: 2.236

5.  A 10-year bibliometric analysis of osteosarcoma and cure from 2010 to 2019.

Authors:  Wacili Da; Zhengbo Tao; Yan Meng; Kaicheng Wen; Siming Zhou; Keda Yang; Lin Tao
Journal:  BMC Cancer       Date:  2021-02-04       Impact factor: 4.430

Review 6.  Insight into the interplay between mitochondria-regulated cell death and energetic metabolism in osteosarcoma.

Authors:  Hong Toan Lai; Nataliia Naumova; Antonin Marchais; Nathalie Gaspar; Birgit Geoerger; Catherine Brenner
Journal:  Front Cell Dev Biol       Date:  2022-08-22

Review 7.  Cell apoptosis, autophagy and necroptosis in osteosarcoma treatment.

Authors:  Jing Li; Zuozhang Yang; Yi Li; Junfeng Xia; Dongqi Li; Huiling Li; Mingyan Ren; Yedan Liao; Shunling Yu; Yanjin Chen; Yihao Yang; Ya Zhang
Journal:  Oncotarget       Date:  2016-07-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.